MHR、RDW、D-二聚体/Fib与慢性心衰血管内皮功能的研究进展  

Research Progress of MHR, RDW, D-Dimer/Fib and Vascular Endothelial Func-tion in Chronic Heart Failure

作　　者：李宁 韩吉祥[2] 

机构地区：[1]青海大学研究生院,青海 西宁 [2]青海大学附属医院,青海 西宁

出　　处：《临床医学进展》2022年第6期5828-5836,共9页Advances in Clinical Medicine

摘　　要：随着我国人口老龄化加剧,心衰已经成为全球严重的公共卫生问题,在心血管疾病中有较高的发病率和死亡率。慢性心衰患者不仅是心脏的泵功能减退。还有由此产生或伴随的复杂分子、神经内分泌、炎症免疫系统的改变。在不同阶段留下了这些生物“标记物”。众所周知,如NT-BNP,BNP等生物标志物已经广泛用于评估心衰病情严重程度及指导临床用药。但易受多种因素影响,因此,寻求心衰新型标志物来评估病情变化程度,指导临床用药及预后变的十分重要。FMD即肱动脉血流调控舒张功能,内皮功能障碍不仅增加动脉硬化风险,还能够预测心血管相关疾病。本文旨在进一步阐述单核细胞/高密度脂蛋白胆固醇(MHR)、RDW、D-二聚体/Fib与慢性心衰FMD的相关性。并进一步为临床评估心衰病情变化及指导临床用药及预后提供可靠依据。With the aging of China’s population, heart failure has become a serious global public health prob-lem, with a high incidence and mortality of cardiovascular diseases. Patients with chronic heart failure don’t just lose pump function. There are also complex molecular, neuroendocrine, inflam-matory and immune system changes that result from or accompany them. These biological “mark-ers” were left behind at various stages. It is well known that biomarkers such as NT-BNP and BNP have been widely used to evaluate the degree of changes in heart failure and guide clinical medica-tion. However, it is susceptible to a variety of factors. Therefore, it is very important to seek new markers of heart failure to evaluate the disease, guide clinical medication and prognosis. FMD refers to the regulation of brachial artery blood flow and diastolic function. Endothelial dysfunction can not only increase the risk of arteriosclerosis, but also predict cardiovascular related diseases. The purpose of this study was to further elucidate the relationship between monocyte/high density lipoprotein cholesterol (MHR), RDW, D-dimer/Fib and FMD chronic heart failure. Furthermore, it provides a reliable basis for clinical assessment of heart failure and guidance of clinical medication and prognosis.

关 键 词：慢性心衰 病情变化 内皮功能障碍 病情严重程度 临床评估 心血管疾病 高密度脂蛋白胆固醇 动脉硬化 

分 类 号：R541.6[医药卫生—心血管疾病]